Mitsuo Terada, MD, PhD@乳腺科医· @MamMa_mimumemo · X·· 2 天前评分70
正文
TALENT試験。HR+/HER2-low早期乳がんに術前T-DXd±アナストロゾール、T-DXd→TCを検討。ORR約65%だがRCB0は3〜9%。ILDは稀。
HER2高発現例でRCB0が多く、治療中HER2は低下。
#ESMO26
621 浏览 · 8 赞 · 1 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Mitsuo Terada, MD, PhD@乳腺科医 · x.com